期刊文献+

单纯膜性肾病与膜性肾病合并意义未明单克隆免疫球蛋白血症的差异性探讨

The difference between simple membranous nephropathy and simple membranous nephropathy combined with unknown monoclonal immunoglobulinemia
下载PDF
导出
摘要 目的探究单纯膜性肾病(MN)患者与MN合并意义未明单克隆免疫球蛋白血症(MGUS)患者的临床病理特征及短期预后的差异。方法选取经肾穿刺活检确诊为MN且合并MGUS的患者41例(MN合并MGUS组)及单纯MN患者81例(单纯MN组)。收集2组患者一般资料及实验室指标[包括白细胞计数(WBC)、血红蛋白(Hb)、血小板(PLT)、尿素氮(BUN)、血肌酐(Scr)、C反应蛋白(CRP)、红细胞沉降率(ESR)、估算肾小球滤过率(eGFR)等];采用间接免疫荧光法测定血清抗M型磷脂酶A2受体(PLA2R)抗体;采用免疫固定电泳测定MN合并MGUS患者M蛋白分型情况;比较2组患者病理资料差异;随访患者的治疗效果及不良反应发生情况。结果与单纯MN组比较,MN合并MGUS组Hb、PLT、eGFR、抗PLA2R抗体水平降低,BUN、Scr、CRP、ESR水平升高(P<0.05)。MN合并MGUS组单克隆免疫球蛋白多为IgG型[41.5%(17/41)]。2组患者病理资料差异均无统计学意义(P>0.05)。MN合并MGUS组、单纯MN组分别有35例、74例获得随访,MN合并MGUS组治疗后缓解率低于单纯MN组[62.9%(22/35)vs.78.4%(58/74),χ^(2)=3.884,P<0.05];Kaplan-Meier曲线显示,MN合并MGUS组累积完全缓解率低于单纯MN组(Log-rankχ^(2)=8.943,P<0.01)。2组不良反应发生率差异无统计学意义(P>0.05)。结论与单纯MN患者相比,MN合并MGUS患者基线肾功能更差,治疗后肾脏缓解率更低。 Objective To explore the difference in clinical pathological characteris clinical pathological characteristics and short-term prognosis between patients with simple membranous nephropathy(MN)and patients with MN complicated with monoclonal gammopathy of undetermined significance(MGUS).Methods Forty-one patients diagnosed with MN combined with MGUS(the MN combined with MGUS group)and 81 patients with simple MN(the simple MN group)diagnosed by renal biopsy were selected in this study.General data and laboratory indicators were collected in the two groups,including white blood cell count(WBC),hemoglobin(Hb),platelet(PLT),urea nitrogen(BUN),serum creatinine(Scr),C-reactive protein(CRP),erythrocyte sedimentation rate(ESR)and glomerular filtration rate(eGFR).Indirect immunofluorescence assay was used to detect serum anti-M-type phospholipase A2 receptor(PLA2R)antibody.M protein typing in patients with MN and MGUS was determined by immunofixation electrophoresis.The difference of pathological data was compared between the two groups.The treatment effect and adverse reactions of patients were followed up.Results Compared with the simple MN group,Hb,PLT,eGFR anti-PLA2R antibody were lower in the MN combined with MGUS group,while expression levels of BUN,Scr,CRP and ESR were higher(P<0.05).Most monoclonal immunoglobulins in patients with MN complicated with MGUS were IgG type[41.5%(17/41)].There was no significant difference in pathological data between the two groups(P>0.05).Thirty-five patients in the MN combined with MGUS group and 74 patients in the simple MN group were followed up respectively.The remission rate after treatment in the MN combined with MGUS group was lower than that in the simple MN group[62.9%(22/35)vs.78.4%(58/74),χ^(2)=3.884,P<0.05].The Kaplan-Meier curve showed that the cumulative complete remission rate of the MN combined with MGUS group was lower than that of the simple MN group(Log-rankχ^(2)=8.943,P<0.01).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Compared with simple MN patients,patients with MN and MGUS have worse baseline renal function and a lower post-treatment renal response rates.
作者 高歌 张鑫越 董奕君 程根阳 GAO Ge;ZHANG Xinyue;DONG Yijun;CHENG Genyang(Department of Nephrology,the First Affiliated Hospital of Zhengzhou University,Zhengzhou 450052,China)
出处 《天津医药》 CAS 北大核心 2023年第8期878-882,共5页 Tianjin Medical Journal
基金 河南省自然科学基金项目(182300410322) 河南省科技攻关计划项目(152102310056)。
关键词 膜性肾病 单克隆免疫球蛋白血症 肾脏缓解率 membranous nephropathy monoclonal gammopathy renal remission rate
  • 相关文献

参考文献2

二级参考文献15

  • 1Kyle RA,Therneau TM, Rajkumar SV, et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance [J]. N Engl J Med,2002,346:564 -569.
  • 2Kyle RA,Themeau TM, Rajkumar SV, et al. Prevalence of monoclonal gammopathy of undetermined significance [ J ]. N Engl J Med,2006,354 : 1362 - 1369.
  • 3Landgren O,Gridley G,Turesson I,et al. Risk of monoclonal gammopathy of undetermined significance ( MGUS ) and subsequent multiple myeloma among African American and white veterans in the United States [ J ]. Blood, 2006,107 : 904 - 906.
  • 4Blade J. Monoclonal gammopathy of undetermined significance [ J]. N Engl J Med,2006,355:2765 - 2770.
  • 5Kyle RA, Blade J, Rajkumar SV. MGUS. In : Malpas JS, Bergsagel DE, Kyle RA, et al, eds. Myeloma: biology and management [ M ]. 3rd ed, Philadelphia: Saunders ,2004:315 - 352.
  • 6International Myeloma Working Group. Criteria for the classification of monoclonal ganunopathies; multiple myeloma and related disorders: a report of the International Myeloma Working Group [ J ]. Br J Haematol, 2003,121:749 - 757.
  • 7Grogan TM. Plasma cell neoplasms [ M ]. World Health Organization Classification of Tumours. IARC Press Lyon ,2001 : 142 - 145.
  • 8武永清.Waldenstrom's巨球蛋白血症//张之南.血液病诊断及疗效标准[M].北京:科学出版社,2007:239-240.
  • 9Gobbi PG, Baldini L, Broglia C, et al. Prognostic validation of the intemational classification of immunoglobulin M gammopathies: a survival advantage for patients with immunoglobulin M monoclonal garmnopathy of undetermined significance? [ J ]. Clin Cancer Res, 2005,11 : 1786 - 1790.
  • 10Kyle RA. " Benign" monoclonal gammopathy - after 20 to 35 years of follow-up[ J]. Mayo Clin Proc, 1993,68:26 -36.

共引文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部